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Abstract We report the first combined analysis of whole-genome sequence, detailed
clinical history, and transcriptome sequence of multiple prostate cancer metastases in a
single patient (A21). Whole-genome and transcriptome sequence was obtained from
nine anatomically separate metastases, and targeted DNA sequencing was performed in
cancerous and noncancerous foci within the primary tumor specimen removed 5 yr
before death. Transcriptome analysis revealed increased expression of androgen
receptor (AR)-regulated genes in liver metastases that harbored an AR p.L702H mutation,
suggesting a dominant effect by the mutation despite being present in only one of an
estimated 16 copies per cell. The metastases harbored several alterations to the PI3K/
AKT pathway, including a clonal truncal mutation in PIK3CG and present in all metastatic
sites studied. The list of truncal genomic alterations shared by all metastases included
homozygous deletion of TP53, hemizygous deletion of RB1 and CHD1, and amplification
of FGFR1. If the patient were treated today, given this knowledge, the use of second-
generation androgen-directed therapies, cessation of glucocorticoid administration, and
therapeutic inhibition of the PI3K/AKT pathway or FGFR1 receptor could provide
personalized benefit. Three previously unreported truncal clonal missense mutations
(ABCC4 p.R891L, ALDH9A1 p.W89R, and ASNA1 p.P75R) were expressed at the RNA
level and assessed as druggable. The truncal status of mutations may be critical for
effective actionability and merit further study. Our findings suggest that a large set of
deeply analyzed cases could serve as a powerful guide to more effective prostate cancer
basic science and personalized cancer medicine clinical trials.
[Supplemental material is available for this article.]
INTRODUCTION
Although whole-genome sequencing (WGS) has been reported from roughly 2500 individ-
ual human cancer primary tumors to date (Ding et al. 2010, 2014; Bass et al. 2011; Berger
et al. 2011, 2012; Chapman et al. 2011; Roychowdhury et al. 2011; Ellis et al. 2012; Egan
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et al. 2012; Govindan et al. 2012; Imielinski et al. 2012; Nik-Zainal et al. 2012; Turajlic et al.
2012; Walter et al. 2012; Welch et al. 2012; Baca et al. 2013; Beà et al. 2013; Brastianos et al.
2013; Brennan et al. 2013; Dulak et al. 2013; Ho et al. 2013; Kan et al. 2013;Morin et al. 2013;
Newburger et al. 2013; Pugh et al. 2013; Zhang et al. 2013; Bruin et al. 2014; Chen et al.
2014, 2015; Morrison et al. 2014; Nadauld et al. 2014; Ouyang et al. 2014; Wang et al.
2014; Andersson et al. 2015; Engle et al. 2015; Cooper et al. 2015; Kovac et al. 2015; Kim
et al. 2015; Yates et al. 2015), only a small number of studies have compared WGS data
from multiple metastatic tumors and primary tumors from the same individual (Gundem
et al. 2015; Hong et al. 2015; Patch et al. 2015). The recent WGS study of multiple prostate
cancer metastases and primary tumor samples from 10 individuals (Gundem et al. 2015) al-
lows comparison of the research value of WGS studies confined to dozens or hundreds of
samples of primary tumors (“wide” studies) versus studies that include both primary andmul-
tiple metastases (“deep” studies). “Wide” studies have begun to establish the landscape of
mutations typical for a given cancer and cohort of patients, whereas “deep” studies allow
phylogenetic tracing and analysis of features of tumor clonality and evolution in response
to therapy and linked to the metastatic phenotype, features that arguably have greater
implications for the development of effective precision treatment of cancer than the catalog-
ing of common mutations.
Combined analysis of primary and metastatic samples from individual prostate cancer
patients is particularly important in light of recent reports showing that lethal metastatic can-
cers can arise from low Gleason grade primary cancer foci in the context of higher Gleason
grade foci in the same patient (Haffner et al. 2013) and that even extensive needle biopsies
may miss the focus of tumor that gives rise to lethal disease (Haffner et al. 2015; Lindberg
et al. 2015).
Here we report the first combined analysis of transcriptome sequence, detailed clinical
history, and whole-genome sequencing of primary tumor sites and multiple metastases
from a single patient (A21), deepening the analysis of this case beyond theWGSdata already
reported in Gundem et al. (2015), and report our findings from the point of view of person-
alized cancer medicine.
RESULTS
Clinical Presentation and Family History
Initial clinical concern was raised when the patient (A21) was found to have elevated serum
prostate-specific antigen (PSA) (25.2 ng/mL) at the age of 65 (Fig. 1A). Prostate digital rectal
examination after the PSA test results were available showed a “large fleshy prostate,
approximately 45–60 grams, with subtle induration located deep within the right base of
the gland. The margins were normal.” Transrectal ultrasound showed “cysts and calcifica-
tions in the central zone compatible with benign prostatic hyperplasia, as well as hypoechoic
nodules in the peripheral zone in themidline, on the right and the left, which were suspicious
for malignancy. The prostate capsule appeared intact and the seminal vesicles appeared
normal.” Prostate biopsy contained adenocarcinoma Gleason score 4 + 3 = 7. Family history
was negative for prostate cancer. A21’s mother died of breast cancer in her 80s. Bone scan
performed 50 d after biopsy diagnosis was suspicious for bone metastasis; follow-up radio-
graphs showed degenerative disk disease, mild osteoporosis, a possible healed rib fracture,
and “no definitive evidence of metastatic foci.” Radical prostatectomy 3 mo after prostate
biopsy contained Gleason 4 + 3 = 7 adenocarcinoma with a minor component of Gleason
grade 5 carcinoma. The right posterior aspect of the prostate contained established capsular
penetration and surgical margin positive for adenocarcinoma. Seminal vesicles, five
right pelvic lymph nodes, and seven left pelvic lymph nodes were negative for tumor.
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Figure 1. Case A21 clinical timeline and pathology-genomic relationships. (A) Clinical events and serum PSA
plotted with time in years on x-axis. (B) Three regions of radical prostatectomy tissueweremicrodissected (nor-
mal stroma, a mixed Gleason 3 +Gleason 5 cancer region, and a region of extraprostatic extension containing
Gleason grade 5 cancer) and compared by targeted sequencing to whole-genome sequence data from nine
metastatic sites. Mutation patterns show that the two primary cancer sites and nine metastatic sites are part
of a clonal cancer lineage, as reflected by accretion of mutations in SPOP, ASNA1, and PIK3CG and others.
The mixed Gleason 3 and Gleason 5 primary cancer region contains the earliest common ancestor identified,
and cancer cells in the region of extraprostatic extension are more closely related to cells in all metastatic
sites studied. All metastatic sites contain a PIK3CG p. R472 missense mutation that was not identified in the
primary cancer. The pattern of spread of the metastatic tumor implied from the genomic data is shown.
Numbers of unique high-confidence somatic mutations identified in metastases are listed in gray and horizon-
tal lines are proportional in length to mutation number, with 1264 mutations shared by all metastases, an
additional 557 somatic mutations unique to A, 178 mutations shared by all other metastases, and so forth.
G, Gleason grade; EPE, extraprostatic extension; LN, lymph node.
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Serum PSA was <0.2 ng/mL, 1.6 yr after initial biopsy diagnosis. Of note, 3.8 yr after prosta-
tectomy, the patient developed bone pain, his PSA elevated to 969 ng/mL, and a bone scan
showed diffuse skeletal metastases. A luteinizing hormone-releasing hormone (LHRH) ana-
log, leuprolide, combined with an antiandrogen, flutamide, was started. Serum PSA
dropped to 0.2 ng/mL and then rose again to 15.8 ng/mL. This was accompanied by reoc-
currence of bone pain 6 mo after beginning leuprolide plus flutamide, at which point the pa-
tient began treatment with a series of corticosteroids (Fig. 1A), as well as estramustine and
vinblastine. Vinblastine treatment was associated with transient decrease in PSA. Of note,
225 d before death, flutamide and leuprolide were stopped according to available records.
The patient developed severe bone pain poorly controlled with opioid and other pain med-
ications, and he elected to undergo intravenous 89Sr radionuclide treatment 46 d before
death frommetastatic prostate cancer. The last measured serum PSA level 64 d before death
was 643.1 ng/mL. The age at prostate biopsy diagnosis of prostate cancer for subject A21
has been shifted by a randomly selected number between −3 and +3 yr in accordance
with study subject’s consent to participate. Clinical values have also been altered to reduce
the risk of reidentification of the subject without altering clinical meaning.
Patient A21 was treated in the 1990s. All of the available PSA, chemotherapy, steroid
therapy, and radiotherapy data for the patient are shown. A21 was not considered for adju-
vant radiotherapy after radical prostatectomy, for unclear reasons. A21 appears to have
avoided returning to his physician after the PSA initially rose to 0.9 ng/mL, after radical pros-
tatectomy, until he developed severe pain. It is also not clear from the available records why
leuprolide and flutamide were stopped 225 d prior to death, when he was transferred to a
long-term care facility. We speculate that since A21’s prostate cancer was progressing de-
spite androgen deprivation therapy (ADT) using leuprolide and flutamide, his clinicians
felt it was no longer needed.
Whole-Genome Sequencing
Weperformedwhole-genome sequencing (WGS) in nine andwhole-transcriptome sequenc-
ing (RNA-seq) in six of the samemetastatic cancer samples obtained in a rapid autopsy study.
Phylogenetic Analysis
Analysis of somatic mutations across metastases revealed the order of clonal evolution from
right rib nodular metastasis through several intermediate locations to four liver sites in the
final stages of the disease (Fig. 1B). This was confirmed by analysis of DNA rearrangements
and somatic copy-number alterations (Supplemental Figs. 1 and 2). The chain-like rearrange-
ments suggestive of chromoplexy present only in these liver metastases demonstrate that
major genome crisis events continue to occur during cancer progression (Baca et al. 2013).
All metastases showed amplification of the androgen receptor (AR) locus (Fig. 2A). AR lo-
cus instability was characterized by four distinct patterns suggesting that AR instability arose
independently in the four earliest metastatic sites, consistent with sudden strong selection
pressure to maintain androgen signaling after onset of ADT (Palmberg et al. 2000) (see
Methods). We additionally found evidence for a late-stage AR p.L702H missense mutation
in all four liver metastases (Table 1). The mutant allele fraction indicated a single mutant
copy of AR in the setting of ∼16-fold AR amplification (Fig. 2B). The left adrenal metastasis
also yielded a single p.L702H read, but sequencing error could not be ruled out (Fig. 2B).
Noneof themetastases showedevidenceof significant expressionofARcryptic exonvariants.
Transcriptome Sequencing
RNA-seq in the six metastatic sites demonstrated significant up-regulation of androgen-reg-
ulated genes in samples with the AR p.L702H mutation (Fig. 2C). The p.L702H mutant is
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known to have increased affinity for glucocorticoids leading to AR transactivation (Zhao et al.
2000; Carreira et al. 2014). If a patient with similar findings were alive today, detection of mu-
tant AR might indicate halting corticosteroid treatment, with potential benefit to the patient.
The findings indicate that the AR locus can be targeted by two hits (AR amplification and
Figure 2. Evolution of androgen receptor (AR) region X Chromosome alterations by whole-genome and tran-
scriptome sequencing in caseA21. (A)AR regional structural instability signature in earliermetastases (right rib,
left iliac crest, left clavicle LN, and left adrenal) in the clonal evolution map shown in Figure 1B contain four
distinct patterns, the latter of which (left adrenal) is shared by all subsequent sites on the map, suggesting in-
dependent evolutionary selection of distinct AR structural response to androgen deprivation therapy (ADT) in
at least these four studied independent sites. Whether these assorted AR-mutated subclones existed in small
numbers before selection cannot be determined from the current study. (B) All four liver metastases and the
left adrenal metastasis contained an AR p.L702H mutation in one copy of AR. The mutation is also present in
the RNA-seq data from the same samples. The L702H mutant modifies the AR ligand binding domain and is
known to alter ligand specificity, rendering the protein responsive to glucocorticoids administered during
A21’s treatment shown in Figure 1A (Zhao et al. 2000; Carreira et al. 2014). (C ) Liver metastases containing
the AR p.L702H mutation exhibited significantly increased expression of androgen-regulated genes KLK3,
ACPP, FKBP5, SLC45A3, and PCA3 as compared with three metastatic sites where the AR p.L702H was not
detected (∗P< 0.05, ∗∗P < 0.01 and ∗∗∗P< 0.001; see Methods).
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mutation), underscoring the importance of androgen signaling in prostate cancer progres-
sion. All of the patient’s sequenced metastases were negative for ETS (E26 transformation
specific) fusions.
Targeted Sequencing
To trace the origin of the alterations found in the metastases, we performed targeted se-
quencing of three foci in the prostate: a region containingmixed Gleason grade 3 and 5 can-
cer, a region of extraprostatic extension (EPE) containing Gleason grade 5 cancer, and a
region of noncancerous prostate stroma (Fig. 1B). Based on sequence analysis of these
foci, the metastases most closely match mutations found in the region of EPE. Both the re-
gion of mixed Gleason 3 and Gleason 5 cancer and the region of Gleason 5 EPE contain a
SPOP p.F102C mutation (Barbieri et al. 2012).
DISCUSSION
Examining the findings in the metastases at the AR locus together with the clinical timeline,
we speculate that metastatic prostate cancer subpopulation selection occurred in three
phases. Phase 1 occurred at the time of initial ADT, when four independent AR-amplified
subclones emerged in four separate locations (Figs. 1A and 2A). Phase 2 is indicated by
the emergence of an AR p.L702H mutation conferring glucocorticoid responsiveness
(Figs. 1A, 2B,C). Phase 3 occurred when leuprolide and flutamide treatment were stopped
225 d before death, when the most highly androgen-plus-corticosteroid responsive sub-
clone rapidly emerged and populated the liver (Figs. 1A, 2B).
Shared truncal driver mutations in metastases are attractive potential targets for person-
alized therapy. In A21, we found six potentially actionable genomic alterations shared by all
metastases and expressed at the RNA level, including four point mutations and two copy-
number alterations (Supplemental Table 1). The PI3K/AKT pathway harbored several poten-
tially activating alterations, including an AKT3 duplication and PIK3CG p.R472C mutation in
all metastases, and a PIK3CA duplication in all metastases except the right rib metastasis.
The left rib metastasis additionally harbored a private PIK3CA p.Q546K mutation (Table
1). Mutations at this residue disrupt the PI3KCA helical domain and are known to result in
PI3K pathway activation. PIK3CA encodes a catalytic subunit of the class IA phosphoinosi-
tol-3-kinase (PI3K) complex, whereas PIK3CG encodes a catalytic subunit of the class IB
Table 1. Selected missense variants based on whole-genome sequencing
Number of variant reads/total reads
Chr Position Ref Alt Gene AA_Change
Normal
kidney
Right
rib
Left
iliac
crest
Left
clavicle
LN
Left
adrenal
Left
rib
Single
liver 4
Single
liver 8
Single
liver 2
Multi
liver
13
Chr3 178936094 C A PIK3CA p.Q546K 0/33 0/32 0/56 0/33 0/60 18/59 0/48 0/66 0/54 0/37
Chr1 165664551 A G ALDH9A1 p.W89R 0/29 18/29 17/27 16/24 23/37 26/36 22/32 18/29 19/26 21/29
Chr7 106509420 C T PIK3CG p.R472C 0/35 7/25 11/36 12/42 8/24 12/38 8/19 8/24 7/47 15/38
Chr13 95735408 C A ABCC4 p.R891L 0/30 13/24 25/44 25/31 16/26 20/35 20/32 18/27 22/33 15/28
Chr17 47696643 A C SPOP p.F102C 0/35 16/22 7/25 6/18 8/24 14/34 12/20 12/26 16/32 16/29
Chr19 12849387 C G ASNA1 p.P75R 0/33 8/16 13/29 15/30 6/20 9/25 9/19 10/19 16/38 14/33
ChrX 66931463 T A AR p.L702H 0/19 0/176 0/153 0/164 1/83 0/127 8/132 8/91 5/94 4/112
Ref, A21 germline reference allele; Alt, A21 alternative allele; AA_Change, predicted protein amino acid change.
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PI3K complex. Both class I PI3K complexes phosphorylate PIP2 lipids to produce PIP3. PIP3
lipids bind to the plasmamembrane and provide a docking point for AKT family proteins (in-
cluding AKT3) and their upstream activator PDK1, resulting in activated AKT signaling.
Although the biological significance of the PIK3CG p.R472C mutation is unclear, the multi-
ple hits to this pathway suggest that the patient could have benefited from PI3K/AKT path-
way inhibition through drugs such as NVP-BEZ235 or AZD5363. Another potentially
actionable finding was a focal FGFR1 amplification shared by all metastases. Aberrant acti-
vation of fibroblast growth factor receptors by amplification or fusion has been associated
with oncogenic progression in various cancers including prostate cancer (Armstrong et al.
2011), and FGFR1 inhibitors are currently being tested in clinical trials (Dieci et al. 2013).
Three of A21’s clonal truncal mutations (ABCC4 p.R891L, ALDH9A1 p.W89R, and
ASNA1 p.P75R) (Table 1; Supplemental Table 1) were expressed at the RNA level and
were assessed as potentially druggable based on analysis using the Drug–Gene
Interaction Database (Griffith et al. 2013). Although these truncal mutations likely represent
passenger events, they could introduce physiologic vulnerabilities for small-molecule-based
synthetic lethality and/or create novel targets for immunotherapy. Expressed clonal truncal
mutations that fall into this “potentially helpful passenger” category merit further analysis to
determine their true value in advancing cancer precision medicine.
What addedvaluedidWGSprovide in this study?Wouldwhole-exomesequencing (WES)
have provided similar information? WGS was critical for understanding the clonal history of
the metastases, as WES would have reduced the number of informative mutations from
741 to below 20. This number of mutations would not have been sufficient for reconstructing
the clonal history with high confidence. Use of exome sequencing would have also rendered
detailed analysis of the AR copy-number alterations and their breakpoints impossible. These
are research findings with potential clinical import, supporting the further use of WGS in ap-
propriate trials. Nonetheless, using theWGSdata to simulateWES in eachmetastasis studied
in this case shows that 35–43 protein-altering mutations would have been identified, 32 of
which were shared by all metastases (including the four potentially druggable protein-alter-
ing mutations in PIK3CG, ABCC4, ALDH9A1, and ASNA1). A matrix of protein-altering mu-
tations shared by any two metastases shows that the 32 truncal mutations could be
perfectly or nearly perfectly separated from the nontruncal mutations by combining results
of any two bonemetastasis samples or combination of one bone and one visceral metastasis
samples. This finding should be tested in future studies (Table 1; Supplemental Table 3).
How does this case compare to the cases in the recent clinical exome sequencing in ad-
vanced prostate cancer study with 150 patients (Robinson et al. 2015)? Based on Figure 2 in
Robinson et al., Case A21 reported here has interesting similarities to Case 32 in Robinson
et al. These two cases shareAR amplification and loss of both copies of TP53; neither has loss
of PTEN or contains ETS fusions; A21 has missense mutations in one copy of PI3 kinase core
protein PIK3CG; Case 32 has amplification of both copies of PI3 kinase core protein PIK3CB;
both cases show loss of CHD1 (both copies in Case 32, hemizygous in Case A21); and both
have missense mutation of one copy of SPOP. Genomic differences include alterations in
BRCA2 in Case 32 only, and loss of RB1 and TET2 in A21 only. FGFR1 is amplified in A21,
and none is reported for Case 32. Whether these similarities and differences are meaningful
on a biologic or clinical level would requiremore detailed comparison using well-curated da-
tabases and a larger number of cases, but they suggest that the field would likely benefit
from the ability to do such comparisons. In conclusion, analysis of the “deep” data set avail-
able for Case A21 provides biological insights relevant to prostate cancer biology in general
and to Case A21 in particular. These insights are far more useful than what can typically be
obtained from “wide” studies.
In conclusion, this case study suggests that once initial selection of castration-resistant
subclones occurs after initial ADT, androgen responsiveness is nonetheless maintained by
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metastatic cells. Reintroduction of androgen by stopping leuprolide and flutamide and con-
tinuing corticosteroids was associatedwith population of the liver by a clone containing com-
bined amplified wild-type and corticosteroid-sensitive mutant AR. In addition, p.L702H AR
mutation in approximately one of 16 AR copies per cell was associated with activation of an-
drogen-responsive elements as evidenced by RNA-seq. Importantly, this study adds to pre-
vious reports questioning the validity of molecular representation provided by random
biopsies of the primary tumor. To find the best potential novel drug targets for individual pa-
tients, studies are needed to determine optimal sampling regimes, including “liquid” and
metastatic tissue biopsies at different time points, to identify truncal changes, and to detect
therapy-induced changes. Studies fully integrating the entire clinical timeline, pathology,
and genomic findings in individual patients are essential for meaningful progress in under-
standing cancer and can teach the combined research and medical team to identify poten-
tially actionable alterations. We argue that such “deep” studies should become the rule,
rather than the exception. Finally, identification of novel “precision” druggable targets is
just a first step. Currently many patients are not eligible to receive identified targeted drugs
because of limitations in trial and reimbursement mechanisms. New clinical trial and drug ap-
proval and reimbursement mechanisms are needed to allow the cancer precision medicine
concept to find its appropriate use in medical practice.
METHODS
Tissue Microdissection and DNA Isolation
DNA and RNA isolation from the freshly frozen cryostat-microdissected metastases (n = 9;
Fig. 3B) was performed with phenol–chloroform extraction or QIAGEN column extraction.
A noncancerous kidney sample was used as germline reference control. Cancer cell fraction
(CCF) estimated by visual analysis of hematoxylin and eosin–stained dissected tumor sec-
tions and from examination of allelic fractions was between 75% and 90% (mean CCF was
84.6%) for all tumor samples. WGS was performed for all nine metastatic samples and
RNA-seq was performed in six of the same metastatic tissue materials (alternating sections
used for DNA or RNA isolation). Laser microdissection of selected foci (Fig. 1B) from the
prostate removed 5 yr before death was performed using Arcturus and MMI dissection sys-
tems. DNA isolation was performed using QIAGEN FFPE kits.
Whole-Genome Library Construction and Sequencing
Genomic DNA was sheared into 500-bp fragments using a Covaris E210 ultrasonicator.
Overhangs were converted into blunt ends using T4 DNA polymerase and Klenow enzyme.
An adeninewas added to the 3′ end of the blunt phosphorylatedDNA fragments, and adapt-
ers were ligated on both ends. Ligated products were purified by agarose gel electrophore-
sis followed by QIAquick gel extraction, to remove residual free and self-ligated adapters
and to select properly sized templates for cluster generation. DNA fragments with adapters
on both ends were amplified using two primers that annealed to the adapters. Polymerase
chain reaction (PCR) products were checked and purified by agarose gel electrophoresis.
The fragment size and molar concentration of each library were determined using the
Agilent 2100 Bioanalyzer and ABI Real-Time PCR System (StepOnePlus), respectively. As
mean fragment size increased to 622 bp after adapter ligation, fragments between 600
bp and 684 bp were selected. An Illumina Cluster Station was used to hybridize samples
onto a flow cell and amplify them for sequencing on Illumina HiSeq 2000. Raw image files
were processed by Illumina pipeline for base-calling with default parameters resulting in
90-bp paired-end reads. Reads with too many N bases (>10%) or low base quality (>50%
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bases with base quality <5) were discarded. Library construction and sequencing was per-
formed at BGI (Hong Kong). Average whole-genome sequence coverage was 30× for can-
cerous and noncancerous samples. Median coverage of coding regions was 23× or higher
in all samples (Table 2). The range of coverage at different depths for each tumor sample
is shown in Supplemental Figure 4.
Targeted Sequencing
To validatemutations found by whole-genome sequencing and to sequencemicrodissected
regions from the primary tumor, targeted sequencing of 88 amplicons (average 150 bp in
length) was carried out using Illumina MiSeq and an Illumina TruSeq Custom Amplicon kit
designed using Illumina Design Studio software. Of the 88 amplicons, 63 amplicons were
targeted at somatic mutations, five targeted at germline single-nucleotide polymorphisms
(SNPs) were used as positive controls, and the remaining 20 were used for assessing copy
number.
The list of 63 somatic mutation targets included 17 protein-altering mutations observed
in all metastases, 16 protein-altering mutations observed in a subset of metastases, and 30
non-CDS (coding sequence) mutations that were validated because they were informative
with regard to the progression model (Supplemental Table 2). Of the 63 targeted mutations,
60 yielded reads, and 57 of 60 (95%) yielded genotype calls identical to those obtained from
whole-genome sequencing. Three targeted mutations yielded low mutant allele fraction in
all samples (including the normal tissue) and were recategorized as sequencing errors.
Amplicons used for copy-number assessment included five amplicons each for TP53,
RB1, CHD1, and the 23-Mb region in Chromosome 2. These four regions were deleted in
all metastases, and the amplicons were included to assess their copy number in the prosta-
tectomy sample.
Whole-Transcriptome Library Construction and Sequencing
RNA isolated from seven of the metastases underwent transcriptome sequencing. Beads
with oligo(dT) were used to isolate poly(A) mRNA after collection of total RNA.
Fragmentation buffer was added to shear mRNA into short fragments and to synthesize
the first-strand cDNA with random hexamer primers. The second-strand cDNA was synthe-
sized using buffer, dNTPs, RNaseH, and DNA polymerase I, respectively. Short fragments
Table 2. The coverage of the whole-genome and whole-transcriptome sequencing
Sample
Whole-genome sequencing Whole-transcriptome sequencing
Total reads
Aligned
(%)
Median CDS
coverage Total reads
Aligned
(%)
mtRNA
(%)
Right rib 1,200,343,314 93 26 108,387,928 68 15
Left iliac crest 1,379,274,636 94 37 105,250,920 55 10
Left clavicle LN 1,126,637,546 93 31 110,086,613 91 82
Left adrenal 1,151,593,908 93 27
Left rib 1,252,845,806 93 30 110,678,869 73 8
Single liver 2 1,481,140,684 91 38 108,970,487 93 9
Single liver 4 1,077,269,004 92 23
Single liver 8 1,164,407,226 92 24 11,237,2452 88 12
Multi liver 13 1,088,762,606 92 28 113,997,841 93 10
Normal kidney 1,169,821,684 91 34
CDS, coding DNA sequence; mtRNA, mitochondrial RNA.
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were purified with the QIAquick PCR Extraction Kit and resolved with elution buffer (EB) for
end reparation and poly(A) addition. After that, the short fragments were ligated to
sequencing adapters and suitable fragments were selected for the PCR amplification as
templates and separated with agarose gel electrophoresis before sequencing. Raw image
files were processed by Illumina Pipeline for base-calling with default parameters resulting
in 90-bp paired-end reads. Reads with too many N bases (>10%) or low base quality
(>50% bases with base quality <5) were discarded. Library construction and sequencing
was performed at BGI, Hong Kong. One transcriptome sample 80% contaminated with mi-
tochondrial RNA (mtRNA) was eliminated from analysis, resulting in six samples with good
quality sequence.
Mutation Analysis
Whole-genome sequencing reads were aligned against the GRCh37 human reference ge-
nome using Bowtie version 2.0.0 (Langmead and Salzberg 2012). Duplicate alignments
were removed using SAMtools rmdup. A somatic mutation was called in a tumor sample if
at least four reads and at least 15% of all reads displayed the mutant allele, and if at most
one read and at most 5% of all reads in the normal kidney sample displayed the same allele.
Pearson’s χ2 test was additionally used to assess the probability that all samples (including
the normal sample) had the same underlying allele fraction (indicating a sequencing error).
Mutations with a P-value > 0.0001 were discarded. Finally, mutations at sites annotated in
the 1000 Genomes database (The 1000 Genomes Project Consortium 2015) with a minor al-
lele fraction above 0.5% were discarded. The ANNOVAR toolkit (Wang et al. 2010) was used
to annotate the genomic locations and predicted consequences of somatic mutations.
Putative Druggable Targets
To identify putative druggable targets, a list of genes with nonsynonymous variants in coding
regions and genes with focal high-level amplification was queried against DGIdb version
1.66 (Griffith et al. 2013).
Identification of Chromosomal Rearrangements
Chromosomal rearrangements were called using the Breakfast algorithm, part of the Pypette
suite (https://github.com/annalam/pypette). Briefly, the software looks for paired-end reads
and individual mates overlapping a chromosomal breakpoint and identifies high-confidence
rearrangements at sites with multiple reads of evidence. Minimum evidence was two paired-
end reads and two individual mates spanning the junction. The normal kidney sample was
used as control to determine somatic rearrangements.
Transcriptome Analysis
The paired-end 90-bp reads fromHiSeq 2000 sequencing were aligned against the GRCh37
reference genome and National Center for Biotechnology Information (NCBI) transcriptome
annotations using TopHat 2.0.6. The alignment statistics of the samples are given in Table 1.
The number of reads aligned to the exons of Ensembl 68 genes were counted using
BEDTools (Quinlan and Hall 2010). Read counts were normalized across samples using me-
dian-of-ratios normalization.
Progression Model
To infer the clonal history of metastases in patient A21, we first constructed amutationmatrix
containing all 741 high-confidence somatic mutations found in exactly two to eight metas-
tases. Mutations found in all metastases or mutations found in only one metastasis provided
no information for clonal inference and were omitted from analysis. Hierarchical clustering of
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the mutation matrix revealed linear accumulation of somatic mutations as new metastases
were seeded from a truncal clone (Supplemental Fig. 3). The most recent common ancestral
clone (MRCAC) of all metastases had acquired 1264 somatic mutations by the time of met-
astatic seeding to the right rib (not shown in the matrix). The MRCAC then acquired 178 ad-
ditional mutations before seeding to the left iliac crest and a further 22 mutations before
seeding to the left clavicle. The clonal history was inferred by considering triplets of metas-
tases. If we denote three arbitrary metastases as A, B, and C, we inferred that metastases B
and C occurred later than metastasis A and shared an ancestral clone with A if (1) metastases
B and C shared a significant number of mutations not present in A; (2) all mutations shared by
A and B were present in C; and (3) all mutations shared by A and C were present in B. We
cannot require that all mutations in A should also be present in later metastases B and C,
because metastasis A will generally have acquired private mutations not present in the
MRCAC of A, B, and C.
Because the mutation matrix only displays mutations shared by two or more metastases,
private mutations are not visible and therefore we observe a clear visual pattern whereby lat-
er metastases carry all of the nonprivate mutations found in earlier metastases (in the ab-
sence of branched evolution).
One interesting outcome of the mutation matrix visualization is that it makes it clear how
copy-number alterations can confound analyses of clonal history. In the mutation matrix for
Patient A21,manymutations observed in the right ribmetastasis were lost in latermetastases
because of deletion events in Chromosomes 2, 6, 7, and 11 (Supplemental Fig. 3). Whole
chromosome deletion of Chromosome 11 occurred as two independent events: once as a
private event in the left clavicle lymph node metastasis, and a second time in MRCAC of
the left rib metastasis and subsequent metastases. In total, 654 of 741 (88.2%) somatic mu-
tations were in perfect agreement with the proposed progression model. Of the 87 muta-
tions that disagreed with the model, 80 were explained by copy-number alterations that
deleted the mutant allele or diluted the mutant allele fraction.
It should be noted that the sequencing data alone is not sufficient for making inferences
about the physical location of the truncal clone fromwhichmetastases were seeded. It is pos-
sible that all metastases were seeded from the right rib metastasis or from a different meta-
static site that was not sequenced or no longer existed at the time of autopsy. It is also
possible that the site fromwhichmetastatic seeding occurred changed its location as the dis-
ease progressed.
Themutationmatrix allows a reader to visually verify the inferred clonal history and clearly
shows the confounding effect of copy-number alterations on clonal inference.
AR Amplification Analysis
We observed four distinct patterns of AR amplification among the nine metastases se-
quenced in this study and hypothesized that these AR amplifications arose independently
in four metastases after ADT initiation. The alternate hypothesis was that theAR amplification
arose in a single metastasis and underwent incremental evolution in clonal descendants
to form the four observed structures. We find that independent evolution is the preferred
hypothesis based on the following observations.
1. A bone scan performed just before starting ADT revealed multiple diffuse skeletal me-
tastases, suggesting that independent evolution of AR amplifications in spatially disjoint
metastases was possible.
2. No breakpoints were shared by the four distinct AR amplification structures. If incremen-
tal evolution of the AR locus had taken place, numerous shared breakpoints would be
expected.
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3. The structure of the AR locus only differed in the first four metastases. The last six me-
tastases all shared an identical structure of the AR locus. If we assume that incremental
evolution did take place in the first four metastases, why did it cease for the last six
metastases?
AR Target Gene Analysis
In six A21metastatic samples where analyzable transcriptome data were available, AR target
transcript copy was significantly higher in three metastases containing the AR p.L702H mu-
tation (Multi Liver 12, Single Liver 2, Single Liver 8) as compared with three metastatic sites
not containing the AR p.L702H mutation (right rib, left iliac crest, left rib). These differences
are statistically significant by two-tailed t-test with the following P-values: KLK3 (0.0199),
ACPP (0.0344), FKBP5 (0.0344), SLC45A3 (0.000078), and PCA3 (0.0048) (Fig. 2C).
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